Current risk genes for some diseases such as multiple sclerosis (MS) may have emerged in the past as protection against infection by different pathogens. A group of researchers led by scientists from the University of Copenhagen has analyzed the ancient DNA of European populations and has revealed how MS, Alzheimer’s disease (AD) and diabetes arose as populations migrated. This evolution would explain the modern genetic diversity and the incidences of these pathologies observed today in the old continent.
Keiferx LLC has expanded its exclusive licensing agreement with Georgetown University to advance the development of novel tyrosine kinase inhibitor (TKI) chemical entities for the treatment of multiple disease indications.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described indazole macrocycles acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory, neurological, metabolic, cardiovascular and eye disorders.
Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd. has received FDA clearance of its IND application for a phase I trial in the U.S. of ABP-745, an anti-inflammatory oral small-molecule drug, for the treatment of acute gout.
Novel non-addicting analgetic therapies are urgently needed to reduce the use of opiates as painkillers. With the recent discovery that nicotinic acetylcholine receptors (nAChRs) in the immune system can be stimulated to decrease the release of pro-inflammatory cytokines, the cholinergic anti-inflammatory systems (CAS) have generated significant interest in treating pain associated with inflammation.
Matinas Biopharma Holdings Inc. has reported results from a series of in vivo studies demonstrating successful oral delivery of two lipid nanocrystal (LNC)-formulated small single-strand oligonucleotides that specifically target the key inflammatory cytokines TNF-α and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases.
Sudo Biosciences Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of inflammation and autoimmune disease.
Teva Pharmaceutical Industries Ltd. and Biolojic Design Ltd. have announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of atopic dermatitis and asthma.
RSS
